Latest news

• Biosimilar Lantus leads CHMP opinions

  event. In addition GE Healthcare received a positive opinion for Vizamyl (flutemetamol) as a diagnostic for Alzheimer's disease.

• CHMP backs Piramal's Alzheimer's imaging agent

  18F) and GE Healthcare's Vizamyl (flutemetamol F18) on the market.

• FDA approves Alzheimer's diagnostic drug

  The Food and Drug Administration's (FDA) recommendation for Vizamyl (flutemetamol F 18 injection) means the drug, marketed by GE Healthcare, is the second brain imaging agent approved in the US

• Medicare puts brake on Lilly's Alzheimer's test

  for the disease are in late-stage development, such as GE Healthcare's flutemetamol and Bayer's florbetaben.

• Lilly gets go-ahead for Alzheimer’s diagnostic in EU

  The CMS may change its position given that competing PET imaging agents for Alzheimer's are coming through development, notably GE Healthcare's flutemetamol and Bayer's florbetaben, both of which